GFAP: Novel Test for a Newly Identified Meningoencephalomyelitis

Mayo Clinic

Meningoencephalomyelitis is swelling of the brain or spinal cord caused by an autoimmune reaction. Symptoms include headaches, progressive weakness, confusion and blurred vision. This condition can be treated with steroid therapy, but it is often misdiagnosed as meningitis, encephalitis, myelitis, or a variety of other conditions.

Researchers have developed a unique test to detect a novel form of the disease known as autoimmune glilial fibrillary acidic protein (GFAP) astrocytopathy. This test would be part of encephalitis and myelopathy evaluations. The recommended test involves a test of the patient’s spinal fluid, as well as a serum test.

Toman, Barbara J. “GFAP: Novel Test for a Newly Identified Meningoencephalomyelitis.” Mayo Clinic Laboratories, https://news.mayocliniclabs.com/2019/06/28/gfap/.

Eagle Biosciences offers the most sensitive assays available worldwide in simple-to-use ELISA and Chemiluminescence formats for detecting GFAP: